A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin

(2011) David Kaluza et al.   EMBO JOURNAL

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

A work in progress: The clinical development of histone deacetylase inhibitor

(2010) Silvia Marsoni et al.   Epigenetics

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

(2010) Kyle V. Butler et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

(2009) Melissa J LaBonte et al.   BMC Medical Genomics

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis

(2009) Junichi Kawada et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Function of Histone Deacetylase 6 as a Cofactor of Nuclear Receptor Coregulator LCoR

(2009) Ana Palijan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

HDAC6 is a target for protection and regeneration following injury in the nervous system

(2009) M. A. Rivieccio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide

(2009) Q.-D. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MCF-7 breast carcinoma cells do not express caspase-3

(2008) Reiner U. Jänicke   BREAST CANCER RESEARCH AND TREATMENT

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis

(2008) Y.-S. Lee et al.   CANCER RESEARCH

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

(2008) S Balasubramanian et al.   LEUKEMIA

Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901

(2008) J. Leyton et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic application of histone deacetylase inhibitors for central nervous system disorders

(2008) Aleksey G. Kazantsev et al.   NATURE REVIEWS DRUG DISCOVERY

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation

(2008) R. B. Parmigiani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

(2007) David J. Witter et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS